Share on StockTwits

Research analysts at Cantor Fitzgerald assumed coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a report released on Tuesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $17.00 price target on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 150.74% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. Analysts at William Blair initiated coverage on shares of Agile Therapeutics in a research note on Tuesday. They set an “outperform” rating on the stock. Separately, analysts at Janney Montgomery Scott initiated coverage on shares of Agile Therapeutics in a research note on Tuesday. They set a “buy” rating and a $18.00 price target on the stock. Finally, analysts at RBC Capital initiated coverage on shares of Agile Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $12.00 price target on the stock.

Agile Therapeutics (NASDAQ:AGRX) traded up 7.96% during mid-day trading on Tuesday, hitting $7.32. 276,828 shares of the company’s stock traded hands. Agile Therapeutics has a 52 week low of $5.05 and a 52 week high of $6.92. The stock has a 50-day moving average of $6.14 and a 200-day moving average of $6.14. The company’s market cap is $136.1 million.

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company focused on the development and commercialization of new prescription contraceptive products.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.